Cemiplimab: a new option for the treatment of non-small-cell lung cancer

Future Oncol. 2021 Jul;17(20):2559-2562. doi: 10.2217/fon-2021-0343. Epub 2021 May 28.

Authors

Nadine Khalife¹, Manal Kordahi², Tony Felefly³, Khalil Saleh⁴

Affiliations

¹ Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
² National Institute of Pathology, Baabda, 1003, Lebanon.
³ Department of Radiation Oncology, Hotel-Dieu de France University Hospital, School of Medicine, Saint-Joseph University, Beirut, 1100, Lebanon.
⁴ Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

PMID: 34047193
DOI: 10.2217/fon-2021-0343

No abstract available

Keywords: PD-L1; atezolizumab; brain metastases; cemiplimab; non-small-cell lung cancer; pembrolizumab.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Prognosis

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
cemiplimab